Clinical trials: Stage IV Small Cell Lung Cancer
Lung Cancer
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well…
- Trial name
- NCT00534209
- Testing
- Allogeneic B7.1/HLA-A1
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Stage IV or Recurrent Non-Small Cell Lung Cancer
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
- Trial name
- NCT02041533
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 141 sites in United States, Argentina and 24 more
- Volunteers
- 541 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01935336
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Colorado, Denver
Non-small Cell Lung Cancer (NSCLC)
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or…
- Trial name
- SOLAR (NCT02588261)
- Testing
- naquotinib mesilate, Erlotinib, Gefitinib
- Where
- 167 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one…
- Trial name
- NCT00065182
- Testing
- Topotecan/Docetaxel combination, Docetaxel
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00362882
- Testing
- docetaxel, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin +…
- Trial name
- NCT02367794
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody, Carboplatin, Nab-Paclitaxel
- Where
- 242 sites in United States, Argentina and 24 more
- Volunteers
- 1,021 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00103207
- Testing
- cetuximab
- Where
- 157 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eastern Cooperative Oncology Group
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01259089
- Testing
- erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by…
- Trial name
- NCT04081688
- Testing
- Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This randomized phase II trial studies how well erlotinib hydrochloride (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor…
- Conditions
- EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01532089
- Testing
- Bevacizumab, Erlotinib, Erlotinib Hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Academic and Community Cancer Research United
Non-small Cell Lung Cancer
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00606502
- Testing
- Pralatrexate, Erlotinib, Vitamin B12
- Where
- 47 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Trial name
- NCT01737502
- Testing
- Auranofin, Sirolimus, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer Stage IV
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
This is a multicenter, national, nonrandomized, phase II trial in subjects with nonsquamous NSCLC patients that have untreated asymptomatic BM.
- Trial name
- ATEZO-BRAIN (NCT03526900)
- Testing
- Atezolizumab
- Where
- 15 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Spanish Lung Cancer Group
Lung Cancer
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01041781
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 400 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
This research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer.
- Trial name
- NCT01620190
- Testing
- Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with stage IIIB, stage IV, or recurrent non-small…
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00459342
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche